Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + dexamethasone vs BiRd as initial therapy in multiple myeloma
2015-001183-19Phase 3Active
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Progression-Free Survival. Started Jul 2015; status: active.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-001183-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001183-19.